- Home
- Products
- Customized ADCs
- CXCL10
- Anti-CXCL10 (Eldelumab)-MC-MMAF ADC
Anti-CXCL10 (Eldelumab)-MC-MMAF ADC (CAT#: ADC-W-1012)
This ADC product is comprised of an anti-CXCL10 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CXCL10
- Alternative Names
- CXCL10; chemokine (C-X-C motif) ligand 10; INP10, SCYB10, small inducible cytokine subfamily B (Cys X Cys), member 10; C-X-C motif chemokine 10; C7; crg 2; gIP 10; IFI10; IP 10; mob 1; gamma IP10; gamma-IP10; small-inducible cytokine B10; interferon-induc鐰ҧ宰̟
- Target Entrez Gene ID
- 3627
- Target UniProt ID
- P02778
- Overview
- This antimicrobial gene encodes a chemokine of the CXC subfamily and ligand for the receptor CXCR3. Binding of this protein to CXCR3 results in pleiotropic effects, including stimulation of monocytes, natural killer and T-cell migration, and modulation of
- Overview
- Human Anti-CXCL10 IgG1-kappa antibody, Eldelumab
- Generic name
- Eldelumab
- Host animal
- Human
- Species Reactivity
- Human
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-MUC1 (Nacolomab tafenatox)-SPDB-DM4 ADC (CAT#: ADC-W-1629)
- Anti-CD33mAb-DOTA-SH ADC (CAT#: ADC-W-360)
- Anti-CMV (Sevirumab)-SMCC-DM1 ADC (CAT#: ADC-W-1976)
- Anti-MUC1 (Epitumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1627)
- Anti-CTLA4 (Ticilimumab)-SMCC-DM1 ADC (CAT#: ADC-W-1004)
- Anti-PCSK9 (Evolocumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2381)
- Anti-RTN4 (Ozanezumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1745)
- Anti-IL22 (Fezakinumab)-SMCC-DM1 ADC (CAT#: ADC-W-1340)
- Anti-IL4 (Pascolizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1381)
- Anti-PCSK9 (Bococizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2231)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1012. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-1011 | Anti-CXCL10 (Eldelumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-1015 | Anti-CXCL10 (Eldelumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-1014 | Anti-CXCL10 (Eldelumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-1010 | Anti-CXCL10 (Eldelumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-1013 | Anti-CXCL10 (Eldelumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
CAT# | Product Name | Linker | Payload |
ADC-W-537 | Anti-TPBG-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-515 | Anti-EGFR (ABT-806)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-493 | Anti-CD19 (clone huB4)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-485 | Anti-EphA2 (clone 1C1)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-517 | Anti-TM4SF1 ( clone v1.10)-Mc-LP2 ADC | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
CAT# | Product Name | Linker | Payload |
ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-AA-063 | Anti-HIgG(Fab)-N-MMAF ADC | Noncleavable linkers | MMAF |
ADC-W-2579 | Anti-CEACAM5-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-AA-064 | Anti-HIgG(Fab)-C-MMAF ADC | Cleavable linkers | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.